Reuters logo
2 months ago
BRIEF-Trial results suggest that Camurus' CAM2038 formulations would be effective in reducing illicit opioid use, relapse
June 22, 2017 / 6:14 AM / 2 months ago

BRIEF-Trial results suggest that Camurus' CAM2038 formulations would be effective in reducing illicit opioid use, relapse

June 22 (Reuters) - CAMURUS AB:

* LONG-ACTING BUPRENORPHINE BLOCKS OPIOID EFFECTS AND SUPPRESSES WITHDRAWAL SYMPTOMS IN ADULTS WITH OPIOID USE DISORDER

* STUDY ATTAINED PRIMARY ENDPOINT FOR BOTH ARMS OF CAM2038 DOSING LEVELS BY PRODUCING AN IMMEDIATE AND SUSTAINED BLOCKADE OF HYDROMORPHONE EFFECTS AND SUPPRESSION OF WITHDRAWAL

* CAM2038 WAS SAFELY TOLERATED, WITH ADVERSE EVENTS CONSISTENT WITH OTHER TRIAL RESULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below